latest update:
[TrialBase DB]

trial summary · NCT07215858

BPL-1357 Against H1N1 Influenza Virus Challenge

Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BPL-1357 Against H1N1 Influenza Virus Challenge

Trial record from the TrialBase DB dataset, status RECRUITING, condition Influenza, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07215858phase PHASE2enrollment 129start 2026-11-04

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital. ...

Source record: https://clinicaltrials.gov/study/NCT07215858

Facts

registry idNCT07215858
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionInfluenza
sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
sponsor classNIH
enrollment129
start date2026-11-04
primary completion2028-03-01
completion2028-03-01
results postednot reported

Conditions

  • Influenza
  • Human

Interventions

  • BPL-1357 IM
  • BPL-1357 IN
  • Placebo IM
  • Placebo IN

Countries

  • United States

Intervention types: BIOLOGICAL, OTHER

Work with this record